Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review
Hematology/Oncology and Stem Cell Therapy · 2023
DOI: 10.1016/j.hemonc.2020.07.001 ↗Kurz gefasst
Fallbericht in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2023. Verfasst von Nishant Jindal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, 4th floor, Nehru Hospital, Post Graduate Institute of Medical Education and Research, Sector 12 Chandigarh (160012),…. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Multiple Myeloma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, 4th floor, Nehru Hospital, Post Graduate Institute of Medical Education and Research, Sector 12 Chandigarh (160012), India.
- Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Zitieren
APA
Jindal, N., Jandial, A., Jain, A., Lad, D., Prakash, G., Khadwal, A., Nada, R., Sethi, J., Ahluwalia, J., & Malhotra, P. (2023). Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.1016/j.hemonc.2020.07.001
Vancouver
Jindal N, Jandial A, Jain A, Lad D, Prakash G, Khadwal A, et al. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review. Hematology/Oncology and Stem Cell Therapy. 2023. doi:10.1016/j.hemonc.2020.07.001
BibTeX
@article{Jindal2023,
author = {Jindal, Nishant and Jandial, Aditya and Jain, Arihant and Lad, Deepesh and Prakash, Gaurav and Khadwal, Alka and Nada, Ritambhra and Sethi, Jasmine and Ahluwalia, Jasmina and Malhotra, Pankaj},
title = {Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review},
journal = {Hematology/Oncology and Stem Cell Therapy},
year = {2023},
doi = {10.1016/j.hemonc.2020.07.001}
}
EUVIMED